To appraise the clinical and cost effectiveness of brigatinib within its marketing authorisation for untreated ALK-positive metastatic non-small-cell lung cancer.
 
Status In progress
Process STA 2018
ID number 1468

Provisional Schedule

Committee meeting 04 November 2020
Expected publication 27 January 2021

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Consultees

Companies sponsors Brigatinib (Takeda)
Others Department of Health
  NHS England
Patient carer groups ALK Positive UK
  Roy Castle Lung Cancer Foundation
Professional groups British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Roche (Alectinib)
General commentators All Wales Therapeutic and Toxicology Centre
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency

Timeline

Key events during the development of the guidance:

Date Update
05 March 2020 Invitation to participate
20 January 2020 - 17 February 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
16 December 2019 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer. Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early March 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.
13 June 2019 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer. Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late -November 2019. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.
25 January 2019 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer. Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-August 2019.
02 October 2018 - 30 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
18 April 2018 In progress. Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance